In summary, we found that modulating the PPARγ pathway increases NECTIN4 expression, which we leveraged by repurposing a diabetes drug, rosiglitazone, to increase targeting and anti-tumor efficacy of NECTIN4-CAR T cells. The gene discussed is NECTIN4; the disease is diabetes mellitus.